Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-24
DOI
10.1038/s41467-020-16048-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Treatment of murine lupus with TIGIT-Ig
- (2019) Shuowu Liu et al. CLINICAL IMMUNOLOGY
- Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation
- (2018) Pan Liu et al. KIDNEY INTERNATIONAL
- Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy
- (2017) Jan Wysocki et al. KIDNEY INTERNATIONAL
- The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
- (2016) P. Collins et al. HAEMOPHILIA
- Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR/ERK signaling in apolipoprotein E-deficient mice
- (2016) Lai-Jiang Chen et al. PEPTIDES
- Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus
- (2016) Hongjing Gu et al. Scientific Reports
- Novel RAAS agonists and antagonists: clinical applications and controversies
- (2015) Cesar A. Romero et al. Nature Reviews Endocrinology
- Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
- (2014) Zhen Zou et al. Nature Communications
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
- (2013) Manuel Haschke et al. CLINICAL PHARMACOKINETICS
- Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia
- (2013) Amy Shapiro EXPERT OPINION ON BIOLOGICAL THERAPY
- Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
- (2013) Shi Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prevention of Angiotensin II–Mediated Renal Oxidative Stress, Inflammation, and Fibrosis by Angiotensin-Converting Enzyme 2
- (2010) JiuChang Zhong et al. HYPERTENSION
- Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2
- (2009) Jan Wysocki et al. HYPERTENSION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started